PPARG and fatty liver disease: Thiazolidinediones, which selectively act on PPARG, are of particular interest not only for their efficacy in glycemic control but also for their ability to reduce lipotoxicity by lowering free fatty acid levels and improving hepatic steatosis associated with MASLD, thereby promoting healthy adipose tissue expansion [72, 73].